MedTrace Logo

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS

NCT06189833 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-04-23

No results posted yet for this study

Summary

This is a multicenter, single arm, open-label, Phase 2 study in mutiple myeloma with newly diagnosed and treatment-naïve participants for whom high-dose therapy and autologous stem cell transplantation is part of the intended treatment plan. The study is evaluating a technique called Mass Spectrometry Minimal Residual Disease (MS-MRD) using blood samples and compares it with the minimal residual disease (MRD) technique using bone marrow samples.

Conditions

Interventions

DRUG

Daratumumab

Daratumumab will be administered via a subcutaneous injection (SC)

DRUG

Bortezomib

Bortezomib will be administered via a subcutaneous injection (SC)

DRUG

Lenalidomide

Lenalidomide will be administered orally

DRUG

Dexamethasone

Dexamethasone will be administered orally

Sponsors & Collaborators

  • Janssen Pharmaceutica

    collaborator INDUSTRY

  • Stichting European Myeloma Network

    lead NETWORK

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-23
Primary Completion
2024-12-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • Austria
  • Germany
  • Greece
  • Italy
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06189833 on ClinicalTrials.gov